Cargando…

Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study

BACKGROUND: HER2 (ERBB2) activating mutations are present in 2–3% of lung adenocarcinomas; however, no targeted therapy is approved for HER2-altered lung cancers. A novel pan-HER inhibitor, tarloxotinib, is designed to release the active form (tarloxotinib-E) under hypoxic conditions in tumor tissue...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koga, Takamasa, Suda, Kenichi, Nishino, Masaya, Fujino, Toshio, Ohara, Shuta, Hamada, Akira, Soh, Junichi, Tirunagaru, Vijaya, Vellanki, Avanish, Doebele, Robert C., Mitsudomi, Tetsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435395/ https://www.ncbi.nlm.nih.gov/pubmed/34584864 http://dx.doi.org/10.21037/tlcr-21-216

Ejemplares similares

Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance
por: Nishino, Masaya, et al.
Publicado: (2021)

Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study
por: Ohara, Shuta, et al.
Publicado: (2020)

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
por: Fujino, Toshio, et al.
Publicado: (2022)

Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosis
por: Ohara, Shuta, et al.
Publicado: (2019)

Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC
por: Hamada, Akira, et al.
Publicado: (2022)

Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing
por: Koga, Takamasa, et al.
Publicado: (2023)

Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers—Applications and Limitations
por: Ohara, Shuta, et al.
Publicado: (2021)

Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
por: Soh, Junichi, et al.
Publicado: (2021)

Utility of the Ba/F3 cell system for exploring on‐target mechanisms of resistance to targeted therapies for lung cancer
por: Koga, Takamasa, et al.
Publicado: (2022)

Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges
por: Fujino, Toshio, et al.
Publicado: (2021)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021)

Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer
por: Hamada, Akira, et al.
Publicado: (2021)

Collateral Chemoresistance to Anti-Microtubule Agents in a Lung Cancer Cell Line with Acquired Resistance to Erlotinib
por: Mizuuchi, Hiroshi, et al.
Publicado: (2015)

Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond
por: Suda, Kenichi, et al.
Publicado: (2013)

Inter-tumor heterogeneity of PD-L1 status: is it important in clinical decision making?
por: Suda, Kenichi, et al.
Publicado: (2020)

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
por: Suda, Kenichi, et al.
Publicado: (2020)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

Prognostic role of preoperative fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography with an image-based harmonization technique: A multicenter retrospective study
por: Hamada, Akira, et al.
Publicado: (2023)

Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer
por: Suda, Kenichi, et al.
Publicado: (2015)

Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas
por: Suda, Kenichi, et al.
Publicado: (2019)

Surgical therapy for pulmonary metastasis of breast cancer
por: Soh, Junichi, et al.
Publicado: (2020)

Acquired resistance mechanisms to afatinib in HER2‐amplified gastric cancer cells
por: Yoshioka, Takahiro, et al.
Publicado: (2019)

Antitumor activity of pan‐HER inhibitors in HER2‐positive gastric cancer
por: Yoshioka, Takahiro, et al.
Publicado: (2018)

YES1 activation induces acquired resistance to neratinib in HER2‐amplified breast and lung cancers
por: Takeda, Tatsuaki, et al.
Publicado: (2020)

Progression after spontaneous regression in lung large cell neuroendocrine carcinoma: Report of a curative resection
por: Tomizawa, Kenji, et al.
Publicado: (2015)

Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma
por: Ananthapadmanabhan, Varsha, et al.
Publicado: (2022)

Prognostic Implication of Predominant Histologic Subtypes of Lymph Node Metastases in Surgically Resected Lung Adenocarcinoma
por: Suda, Kenichi, et al.
Publicado: (2014)

Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status
por: Suda, Kenichi, et al.
Publicado: (2017)

Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations
por: Torigoe, Hidejiro, et al.
Publicado: (2018)

Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway
por: Ohtsuka, Tomoaki, et al.
Publicado: (2016)

Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression
por: Sato, Katsuaki, et al.
Publicado: (2016)

Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations
por: Ogoshi, Yusuke, et al.
Publicado: (2019)

Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor in lung cancer
por: Mizuuchi, Hiroshi, et al.
Publicado: (2016)

Prognosis and segment-specific nodal spread of primary lung cancer in the right lower lobe
por: Tomizawa, Kenji, et al.
Publicado: (2015)

A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study)
por: Shibaki, Ryota, et al.
Publicado: (2021)

Antitumor effect of afatinib, as a human epidermal growth factor receptor 2‐targeted therapy, in lung cancers harboring HER2 oncogene alterations
por: Suzawa, Ken, et al.
Publicado: (2015)

Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-Cell Lung Cancer and Its Potential at Clinical Molecular Screening
por: Suda, Kenichi, et al.
Publicado: (2023)

Two new species of Prionomastix Mayr (Hymenoptera: Encyrtidae) with a key to Indian species
por: Krishnachaitanya, Tirunagaru, et al.
Publicado: (2016)

BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
por: Lim, Sun Min, et al.
Publicado: (2023)

Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines
por: Suda, Kenichi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_23ntn90p4jct30qgpi6p9rsm6b